iifl-logo-icon 1
iifl-logo-icon 1
iifl-logo-icon 1
Home

Bal Pharma Ltd Share Price

₹113.76
(0.86%)
Jul 22, 2024|10:19:42 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open₹115
  • Day's High₹115
  • 52 Wk High₹132.45
  • Prev. Close₹112.79
  • Day's Low₹111.6
  • 52 Wk Low ₹81.2
  • Turnover (lac)3.11
  • P/E17.34
  • Face Value₹10
  • Book Value₹67.34
  • EPS6.5
  • Mkt. Cap (Cr.)₹179.79
  • Div. Yield0
No Records Found

Bal Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

₹115

Prev. Close

₹112.79

Turnover(Lac.)

₹3.11

Day's High

₹115

Day's Low

₹111.6

52 Week's High

₹132.45

52 Week's Low

₹81.2

Book Value

₹67.34

Face Value

₹10

Mkt Cap (₹ Cr.)

179.79

P/E

17.34

EPS

6.5

Divi. Yield

0

Bal Pharma Ltd Corporate Action

29 May 2023

12:00 AM

Dividend

Dividend Amount: 1

arrow

14 Aug 2023

12:00 AM

AGM

Announcement Date: 14 Aug, 2023

arrow

30 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

11 Aug 2023

12:00 AM

BookCloser

arrow

20 Nov 2023

12:00 AM

EGM

arrow

Bal Pharma Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center

Demat Account

View More

Trading Account

View More

Bal Pharma Ltd SHAREHOLDING SNAPSHOT

22 Jul, 2024|10:42 AM
Jun-2024Mar-2024Dec-2023Sep-2023
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 4.14%

Foreign: 4.14%

Indian: 47.08%

Non-Promoter- 0.13%

Institutions: 0.13%

Non-Institutions: 48.63%

Custodian: 0.00%

Read More
Share Price

Bal Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

15.69

15.76

15.76

14.17

Preference Capital

0

0

0

0

Reserves

80.34

71.56

63.56

51.77

Net Worth

96.03

87.32

79.32

65.94

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2019Mar-2018

Revenue

249.3

170.67

223.07

209.84

yoy growth (%)

46.07

-23.49

6.3

-7.13

Raw materials

-150.58

-84.21

-116.93

-100.62

As % of sales

60.39

49.34

52.41

47.94

Employee costs

-39.61

-48.76

-48.45

-49.61

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2019Mar-2018

Profit before tax

9.79

-9.07

4.41

8.45

Depreciation

-7.25

-7.02

-6.11

-6.72

Tax paid

-0.69

0.17

2.34

-2.51

Working capital

21.59

-16.12

17.18

19.67

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2019Mar-2018

Growth matrix (%)

Revenue growth

46.07

-23.49

6.3

-7.13

Op profit growth

289.87

-66.75

-10.21

12.42

EBIT growth

551.42

-80.28

-3.55

2.99

Net profit growth

-202.18

-231.68

13.83

11.75

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

339.22

304.22

281.21

250.53

171.09

Excise Duty

0

0

0

0

0

Net Sales

339.22

304.22

281.21

250.53

171.09

Other Operating Income

0

0

0

0

0

Other Income

2.85

0.98

5.15

1.14

1.85

View Annually Results

Bal Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,568.65

123.313,76,323.69867.60.865,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,519.8

76.171,19,994.455310.662,259507.93

Cipla Ltd

CIPLA

1,485.5

32.291,19,928.541,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,144.45

33.511,15,173.541,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,636

25.851,10,759.071,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

View All Peer Comparision

MORE ABOUT Bal Pharma Ltd

Management

Register Office

Registrar Office

Managing Director

Shailesh Siroya

Independent Director

C V Srinivas

Executive Director

Himesh Virupakshaya

Independent Director

H S Venkatesh

Independent Director

Nicola Neeladri

Independent Director

Jatish Sheth

Whole-time Director

Kotian Chittananda Damodar

Company Sec. & Compli. Officer

Abdul Basith

Registered Office

Tel: -

Website: -

Email: -

Registrar Office

Tel: -

Website: -

Email: -

Reports by Bal Pharma Ltd

Summary

Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 87. In Mar.90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The companys product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM.The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named SERVETUS has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market duri
Read More

Company FAQs

What is the Bal Pharma Ltd share price today?

Down Arrow

The Bal Pharma Ltd shares price on N/A is Rs.₹114.05 today.

What is the Market Cap of Bal Pharma Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bal Pharma Ltd is ₹180.25 Cr. as of 22 Jul ‘24

What is the PE and PB ratio of Bal Pharma Ltd?

Down Arrow

The PE and PB ratios of Bal Pharma Ltd is 17.34 and 1.69 as of 22 Jul ‘24

What is the 52 Week High and Low of Bal Pharma Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Bal Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bal Pharma Ltd is ₹81.5 and ₹132.2 as of 22 Jul ‘24

What is the CAGR of Bal Pharma Ltd?

Down Arrow

Bal Pharma Ltd's CAGR for 5 Years at 18.20%, 3 Years at 3.16%, 1 Year at 19.69%, 6 Month at -3.51%, 3 Month at 16.55% and 1 Month at -4.61%.

What is the shareholding pattern of Bal Pharma Ltd?

Down Arrow

The shareholding pattern of Bal Pharma Ltd is as follows:
Promoters - 51.23 %
Institutions - 0.13 %
Public - 48.64 %

QUICKLINKS FOR Bal Pharma Ltd

Information
Share PriceFutures PriceOption Chain
Financials
Profit & LossBalance SheetCash FlowKey Ratios
Results
Quarterly ResultHalf Yearly ResultNine Monthly ResultAnnual Result
News
Company
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

About
IIFL Group
Products & Services
Trading Documentation
Useful Links
ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.